Please login to the form below

Not currently logged in
Email:
Password:

Corlaner

This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

  • Amgen starts shipping Corlaner in US Amgen starts shipping Corlaner in US

    Firm also reports healthy financial growth in the first quarter.  . Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA ... Corlaner (ivabradine) - the first new medicine for chronic

  • FDA clears Amgen's Corlaner for heart failure FDA clears Amgen's Corlaner for heart failure

    The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... Corlaner's approval is based on the results of

  • Amgen banking on three launches in 2015 Amgen banking on three launches in 2015

    year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics